3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Conditions
Leukemia, Hairy Cell
4
Hematologic Neoplasms
4
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasms
2
Multiple Myeloma
2
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Thrombocytosis
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Melanoma
1
Lymphoproliferative Disorders
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid, Acute
1
Leukemia, Myeloid, Accelerated Phase
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Laryngeal Neoplasms
1
Interventions
Counseling
2
Bupropion
2
trametinib
1
motexafin gadolinium
1
dabrafenib
1
cobimetinib
1
Zinc Oxide
1
Vemurafenib
1
Varenicline
1
Tobacco Use Cessation Devices
1
Ritonavir
1
Radiotherapy
1
Quality of Life
1
Psychiatric Rehabilitation
1
Polymerase Chain Reaction
1
Patient Reported Outcome Measures
1
Observation
1
Nicotine Replacement Therapy
1
Nicotine
1
Molecular Diagnostic Techniques
1
Indinavir
1
Immunotherapy
1
Gene Expression Profiling
1
Early Intervention, Educational
1
Drug Therapy
1
Doxorubicin
1
Biological Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Laryngeal Neoplasms
×
Vemurafenib
×
Other hematologic neoplasm
×
Clear all
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled